CN104940770A - Tibetan medicine composition for treating superficial gastritis and application thereof - Google Patents
Tibetan medicine composition for treating superficial gastritis and application thereof Download PDFInfo
- Publication number
- CN104940770A CN104940770A CN201510447729.8A CN201510447729A CN104940770A CN 104940770 A CN104940770 A CN 104940770A CN 201510447729 A CN201510447729 A CN 201510447729A CN 104940770 A CN104940770 A CN 104940770A
- Authority
- CN
- China
- Prior art keywords
- parts
- group
- superficial gastritis
- gastric
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a Tibetan medicine composition for treating superficial gastritis and application thereof. The Tibetan medicine composition is composed of active components prepared from following crude drugs in parts by weight: 50 parts of Tibet inula root, 200 parts of rheum officinale, 100 parts of galanga resurrectionlily rhizome, 250 parts of calcined gypsum and 150 parts of medicine terminalia fruit. The active components can be fine powder obtained after the crude drugs are smashed; or the active components are prepared through the steps that conventionally extracting the Tibet inula root, rheum officinale, galanga resurrectionlily rhizome and medicine terminalia fruit, drying, adding the calcined gypsum and smashing into fine powder. Results of a pharmacodynamic experiment on rats with the superficial gastritis show that after the Tibetan medicine composition is used, body weight is obviously increased; gastric mucosa inflammation can be effectively restrained to reduce pathological damage of the gastric mucosa, stomach circulation blood flow volume is increased, the serum GAS content is reduced, G cell activation is restrained, gastric acid secretion is reduced, injured parts of the gastric mucosa are protected and the Tibetan medicine composition is used for treating chronic superficial gastritis and has a good effect.
Description
Technical field
The present invention relates to a kind of Tibetan medicine prescription for the treatment of superficial gastritis, belong to Tibetan medicine field.
Background technology
Chronic superficial gastritis (CSG) is the gastric mucosal lesions caused by various different pathogeny, with chronic inflammatory cell infiltrations such as gastric mucosa layer mesoplasmatocyte and lymphocytes for main manifestations, and change with the atrophic of gastric mucosa, be chronic gastropathy the most common clinically, there is no the Therapeutic Method of specially good effect at present.
Liuwei Anxiao is loose is the classical proved recipes of Tibetanmedicine, the history of existing more than 100 year, records at present in " Chinese Pharmacopoeia " version in 2010.Its formula consists of Radix Inulae 50g, Radix Et Rhizoma Rhei 200g, Rhizoma Kaempferiae 100g, calcite (forging) 250g, Fructus Chebulae 150g, Tronae 300g, be mainly used in incoordination between the spleen and stomach, stagnant in stop caused stomachache distension, dyspepsia, constipation, dysmenorrhea.Tronae is the main branched crystallization containing sodium carbonate, can disappear stagnant, for cold syndrome of the stomach, and dyspepsia.In the loose side of Liuwei Anxiao, Tronae consumption is very large, is principal agent.
Summary of the invention
An object of the present invention is to provide a kind of Tibetan medicinal composition being used for the treatment of chronic superficial gastritis.
Tibetan medicinal composition of the present invention, the active component be made up of the crude drug of following weight portion forms: Radix Inulae 50 parts, Radix Et Rhizoma Rhei 200 parts, Rhizoma Kaempferiae 100 parts, forge calcite 250 parts, Fructus Chebulae 150 parts.
Active component of the present invention can be the fine powder after described crude drug is pulverized; Also, after the Radix Inulae in described crude drug, Radix Et Rhizoma Rhei, Rhizoma Kaempferiae, Fructus Chebulae can being adopted conventional method extraction, drying, add and forge calcite, be jointly ground into fine powder and obtain.
Another object of the present invention is to provide the application of described Tibetan medicinal composition in preparation treatment chronic superficial gastritis medicine.The various customary adjuvant that when preparing different dosage form, pharmaceutics allows can be added in the active component of described Tibetan medicinal composition, if disintegrating agent, lubricant, binding agent etc. are with the method for Chinese medicinal of routine, be prepared into any one and commonly use peroral dosage form, as powder, pill, capsule, granule, tablet etc.
Beneficial effect of the present invention:
By showing the pharmacodynamics test of rat chronic superficial gastritis, after rat model uses Tibetan medicinal composition of the present invention, body weight shows a marked increase, with normal group zero difference (P > 0.05); Can effectively suppress gastric mucosa inflammation and reduce gastric mucosa pathologic damage, promote stomach blood flow, reduce the content of serum GAS; suppress G cell activation; thus minimizing gastric acid secretion, protection mucosal lesion position, this prescription is used for the treatment of chronic superficial gastritis good effect.
Accompanying drawing explanation
Fig. 1 is normal rat gastric mucosa electron-microscope scanning figure;
Fig. 2 is CSG rat model gastric mucosa electron-microscope scanning figure;
Fig. 3 is vitacoenzyme tablet treatment CSG gastric mucosa electron-microscope scanning figure;
Fig. 4 is Liuwei Anxiao loose treatment CSG gastric mucosa electron-microscope scanning figure;
Fig. 5 is novel composing prescription 1 group treatment CSG gastric mucosa electron-microscope scanning figure;
Fig. 6 is novel composing prescription 2 groups treatment CSG gastric mucosa electron-microscope scanning figure.
Detailed description of the invention
Embodiment 1
Get Radix Inulae 50g, Radix Et Rhizoma Rhei 200g, Rhizoma Kaempferiae 100g, calcite (forging) 250g, Fructus Chebulae 150g, be jointly ground into fine powder, mixing, subpackage, obtains powder 1.
Embodiment 2
Radix Inulae 50g, Radix Et Rhizoma Rhei 200g, Rhizoma Kaempferiae 100g, calcite (forging) 250g, Fructus Chebulae 150g.Above 5 tastes, except calcite (forging), 4 tastes such as all the other Radix Inulae, decoct with water 2 times, 2 hours first times, second time 1 hour, filter, filtrate merges, and is condensed into thick paste, add appropriate amount of starch, mixing, dry, add calcite (forging), be jointly ground into fine powder, mixing, subpackage, obtains powder 2.
Experimental example, pharmacodynamics test to rat chronic superficial gastritis
1 test material
1.1 animal
SD rat, body weight 200 ± 20g, SPF level, male and female half and half, in 6 week age, are provided by Shandong Traditional Chinese Medicine University's Experimental Animal Center.
1.2 medicines and reagent
Vitacoenzyme tablet (lot number: 141009, Beihai Yangguang Pharmaceutical Co., Ltd.); 201209), rat stomach therbligs (MTL) elisa test kit (lot number: 201209, Bio-swamp company) rat stomach secretin (GAS) test kit (lot number:; Pepsin testing cassete (lot number: 20121011, Bioengineering Research Institute is built up in Nanjing); Chloral hydrate (lot number: 20101002, Ke Miou chemical reagent development centre, Tianjin); 2,4,6-picric acid (lot number: 20110904, Guangzhou Chemical Reagent Factory); PBS buffering agents bag (lot number: AR0030, doctor's moral biological engineering company limited).Each medical material provides by Jin He Tibetan medicine limited company.Other reagent is analytical pure or adopts analytical pure provisional configuration.
1.3 key instrument
UV-2450 type Shimadzu ultraviolet spectrophotometer; Shimadzu AUW220D electronic balance; YP10002 toy electronic scale (Shanghai You Ke instrument and meter company limited); HC3018R High speed refrigerated centrifuge (Anhui Zhong Ke scientific instrument company limited); TDL-40B low speed large capacity centrifuge (Anting Scientific Instrument Factory, Shanghai); ML 191 laser doppler flowmetry, Powerlab16/30 16 road Physiological Signal Acquiring System (Australian Adinstruments company); 6219 acidometers (Shanghai Ren Shi Electronics Co., Ltd.); The embedding of EG 1160 histopathology instrument, RM2135 tissue pathological slice machine (German Leica company); ECLIPSE Ti-S ultramicroscope (Japanese Nikon company); BH-2 optical microscope (Japanese Olympus company); S-3000N scanning electron microscope (Japanese Hitachi company); IMARK microplate reader (Bio-Rad company of the U.S.).
2 test methods
2.1 rat chronic superficial gastritis (CSG) model copies
SPF level SD rat, 200 ± 20g, male and female half and half.After adaptability raises 7 days, reject defective animal, be divided into Normal group at random, model copy group.Model copy group ammonia every day 0.02% is freely drunk, and coordinates irregular diet (fasting in 1 day is satiated with food for 2 days) to copy chronic superficial gastritis model simultaneously.Randomly draw rat at 60d, 80d, l00d after starting respectively at modeling and carry out the detection of gastric tissue pathology, to occur that the pathological change decision model of CSG gastric tissue copies successfully, model copy success in 100 days after modeling.
2.2 grouping and administration model copy group rat random packet: novel composing prescription 1 group (embodiment 1 gained powder 1); Novel composing prescription 2 groups (embodiment 2 gained powder 2); Liuwei Anxiao falls apart group; Positive drug vitacoenzyme tablet matched group; Model control group, and together enter test with Normal group.Normal group and model control group gavage every day and medicine group equal-volume water, other group is gavage relative medicine solution respectively, continuous gavage 30 days, once a day, 2.0ml/100g body weight.Dosage is respectively:
Vitacoenzyme tablet matched group: 0.035g/100g
Novel composing prescription 1 group and novel composing prescription 2 groups: 0.09g crude drug/100g
Liuwei Anxiao falls apart group: 0.09g/100g
2.3 statistics and analysis
Result with
represent, data Bian SPSS17.0 software is analyzed.
3 evaluation indexes
The general physiological situation of 3.1 rat and body weight change are observed
During administration, observe rat diet, flooded condition and animal general physiological situation every day, recording exceptional shows, 15,30 days rat body weights after mensuration administration.Have a net increase of with body weight value added for evaluation index, calculate as follows:
Body weight before body weight-administration after body weight net increase (Δ g)=administration.
3.2 mucosal lesion situations are observed
Ligation intestinal tube in 0.3cm place under pyloric ring, is injected the PBS solution of l0mlpH 7.2-7.6, esophagus ligation immediately to gastral cavity by esophagus, take out stomach and be soaked in frozen water.15min tailing edge greater gastric curvature cuts off exposure gastral cavity, exenterates, record mucosal lesion situation.Mucosal lesion rate (%)=mucosal lesion area/gastric mucosa gross area * 100%
3.3 gastric tissue pathologic findings
After terminating experimental period, put to death rat, gastric tissue is fixed by 10% formalin and is carried out routine paraffin wax embedding, section, dye through HE, using chronic inflammatory disease degree, activity level, distortion and interstitial congestion and edema degree three as Score index, every is normal (-), slight (+), moderate (++), severe (+++), finally marks sum for inflammatory appraisal result with body of stomach and pyloric part:
Normal 0 point; Slight 1-4 divides; Moderate 5-8 divides; Severe more than 9 points
3.4 gastric mucosa scanning electron microscopic observations
0.5cm is got after greater gastric curvature is cut off
2pyloric part, pH7.2-7.6PBS buffer salt solution vibration washing 3 times, each 3min, puts into 2.5% glutaraldehyde solution immediately, 4 DEG C of fixing more than 4h.Subsequently, gastric tissue gradient alcohol dehydration, isoamyl acetate are replaced, and vacuum drying, metal spraying, observe under S-3000N scanning electron microscope, records 500,1000,2000 times of lower gastric mucosas and epithelial cell form.
3.5 gastric epithelial cells functional evaluation
After gastric tissue paraffin section, Bian A Lixinlan-Glycoprotein binding method (AB-PAS) dyeing, under high-power biological microscope (400 ×), record pyloric part and independent observation face, 3, each district of pyloric part (each sightingpiston has the superficial epithelial cells of more than 6 continuous linear arrangements at least).Microscope and software observes epithelial cell mucin secretor state, wherein acid mucus is in blue (IPP software is with red-label), and Combination mucus is aubergine (IPP software yellow flag) and epithelial cell is pale red (IPP software is with Green Marker).Calculate the acid mucin index of epithelial cell mucin exponential sum as follows:
Epithelial cell mucin index (%)=(acid mucus area+mixing mucus area/epithelial cell area) × 100%
Acid mucin index (%)=(acid mucus area/epithelial cell area) × 100%
3.6 pepsin activities and pH measure
Rat 10% chloral hydrate (0.35ml/100g) anesthesia layback pose gesture, padded head with higher than stomach position, 0.3cm place ligation under pylorus.After 5 hours, cut off ligation place and collect 5 hours gastric juice with 10ml centrifuge tube, the centrifugal 15min of 4000rpm/min, Aspirate supernatant measurement volumes also proceeds to 2.0mlEP pipe, centrifugal 10min, get supernatant and measure pepsin activity by test kit description, acidity is taken into account accurate pH test paper and is measured pH value.
3.7 stomach microcirculation blood flow quantitative determinations
Rat anesthesia layback pose gesture, under a left side finally helps bone, 0.3-0.5cm is by hair, cut off skin and Musclar layer, cut short lesser gastric curvature place mesentery and fully expose body of stomach, body of stomach microcirculatory blood flow is measured (during test with laser doppler flowmetry pin probes between esophageal arteries,inferior 3-4, normal saline gauze maintenance body of stomach is moistening), at body of stomach and pyloric part intersection (avoiding large artery trunks, vein), measure pyloric part blood flow.
3.8 gastrins (GAS), motilin (MTL) assay
After rat anesthesia, abdominal aortic blood, the centrifugal 15min of 3500rmp/min, measures GAS and MTL content in serum by test kit (elisa method) operational approach.
4 results and analysis
The general physiological situation of 4.1 dosage period rat, changes of body mass
During experimental animal administration, without refusing to eat phenomenon, the mental status is normal, health atremia, writhing, sticks up the phenomenons such as tail, rat nose, eye, oral cavity secretions without exception, eupnea; Model control group is partially yellow by hair.Administration is after 15 days, and compared with model group rats body weight, normal group, novel composing prescription 2 groups and vitacoenzyme tablet group all have remarkable increase, and Liuwei Anxiao falls apart, group, novel composing prescription 1 group compare with model group without significant difference; Administration is after 30 days, and each group rat body weight all has growth, and compare with model control group, novel composing prescription 2 groups, vitacoenzyme tablet group have pole significant difference (P < 0.01), and there were significant differences for novel composing prescription 1 group, and Liuwei Anxiao loose group zero difference; Compare with Liuwei Anxiao group of faling apart, novel composing prescription 2 groups has pole significant difference.Show that Liuwei Anxiao falls apart not obvious on the impact of the body weight of CSG rat, and novel composing prescription 1 group effectively but effect is comparatively slow, novel composing prescription 2 groups of effects are faster and better, similar with vitacoenzyme tablet effect.The results are shown in Table 1.
Table 1 is on the impact of CSG rat body weight
Compare with Normal group, #P<0.05, ##P<0.01; * P<0.05 is compared, * * P<0.01 with model control group; Δ P<0.05 is compared, Δ Δ P<0.01 with Liuwei Anxiao group of faling apart.
4.2 pairs of CSG gastric mucosa damages are observed
Rat stomach dissects gross examination of skeletal muscle, and rats in normal control group gastric mucosa smooth pliable, in Chinese red; Model control group rat mucosa congestion and edema, is dispersed in point-like, speckle or strip hemorrhage and rotten to the corn, visible remote hemorrhage point and fresh petechia.IPP software analysis is known, and chronic superficial gastritis model control group animal bleeds point or speckle area increase, and mucosa injury rate is high.Novel composing prescription 1,2 groups and the administration of vitacoenzyme tablet group are after 30 days, gastral cavity mucosa comparatively smooth pliable, in pale red, petechia or speckle area reduce, mucosa injury rate compares with model control group, inequality heteropole its significantly (P < 0.01), and Liuwei Anxiao group of faling apart also is significantly improved effect (P < 0.05).The results are shown in Table 2.
Table 2 is on the impact of CSG rat mucosa injury
| Group | Number of animals (n) | Mucosa injury rate (%) |
| Normal group | 10 | 24.5 |
| Model control group | 10 | 90.8## |
| Vitacoenzyme tablet group | 10 | 32.7** |
| Liuwei Anxiao falls apart group | 10 | 69.4* |
| Novel composing prescription 1 group | 10 | 34.7**Δ |
| Novel composing prescription 2 groups | 10 | 35.8**Δ |
Compare with Normal group,
#p<0.05,
##p<0.01; * P<0.05 is compared, * * P<0.01 with model control group; Compare with Liuwei Anxiao group of faling apart
Δp<0.05,
Δ Δp<0.01.
4.3 pairs of CSG rat stomach Histopathology Effect
Normal group gastric mucosa glandular tube marshalling, size shape is consistent, and in single-column shape, the arrangement of gastric gland body is closely neat, and parietal cell, chief cell boundary clear, have no inflammatory cell infiltration in lamina propria, Submucosa without or slightly slight edema; Model control group gastric gland pipe is disorderly or density is uneven, mucous layer is congested edema, visible a large amount of epithelial cell necrosis comes off, Submucosa edema is obvious, simultaneously mucosa lamina propria and muscularis mucosae is thinning, disorderly, lower edge defect, Submucosa inflammatory cell is common and move to mucous layer, and mucosa lamina propria occurs that inflammatory cell infiltration is (based on lymphocyte and eosinophilic granulocyte, a small amount of neutrophilic granulocyte), degree is based on slightly.Administration is after 30 days, and novel composing prescription group gastric mucosa lamina propria inflammatory cell number reduces, and gastric gland arrangement is slightly neatly smooth and glandular tube structure is regular gradually.Result shows, and novel composing prescription 1,2 groups has remarkable inhibitory action to chronic superficial gastritis gastric tissue pathological change.Compare with model control group and Liuwei Anxiao group of faling apart, the gastric tissue histological scores of novel composing prescription group rat significantly reduces (P<0.05).Adopt rank test, the results are shown in Table 3.
Table 3 is on the histopathologic impact of CSG rat stomach
Compare with Normal group,
#p<0.05,
##p<0.01; * P<0.05 is compared, * * P<0.01 with model control group; Compare with Liuwei Anxiao group of faling apart
Δp<0.05,
Δ Δp<0.01.
4.4 pairs of CSG gastric mucosa scanning electron microscope analysis results
Rats in normal control group gastric mucosa is separated into many area gastricas by crisscross ditch, demarcates clear, in mesh-shape, have many gastric pitss (gastric gland opening) in area gastrica, gastric pits is gyrus shape, and wall liner has circle or oval epithelial cell, volume is basically identical, and queueing discipline; CSG rat model gastric mucosa structure is smooth, area gastrica boundary is unclear, little recess distortion, not of uniform size, be uneven, skewness, epithelial cell is flat and have diabrosis, erosion and come off, and forms microulceration and rotten to the corn face, and to external expansion centered by routed field, extruding, destruction adjacent cells, cause cell shape and irregular arrangement.In addition, rat model gastric mucosa visible red cell, inflammatory cell ooze out, the pleat height that swells rises and falls, the not first-class mucosa injury performance of width; Novel composing prescription 1,2 groups, the crisscross ditch of gastric mucosa stomach deepens, dike shape protuberance reduces, and gastric pits arrangement gradually rule, area gastrica boundary is clear, mucosal epithelial cells swelling shape, adhesion, but structure, form are normal, necrosis comes off minimizing, and mucous membrane surface is presented rotten area and obviously reduced.(see Fig. 1-Fig. 6).
4.5 impacts on CSG gastric mucosa epithelial cells function
Result visible Normal group outermost layer acid slime layer indigo plant dye is complete, continuous, resists the damage of acidic gastric juice to mucosa lamina propria; Model control group due to acid slime layer be destroyed, blued area reduce and discontinuous.After administration, Mucosa Barrier integrity recovers gradually, and novel composing prescription 1 group and model control group and Liuwei Anxiao group of faling apart compares, and the acid mucin index of epithelial cells mucin exponential sum significantly increases; Novel composing prescription 2 groups compares with model control group that there were significant differences, and loose to organize comparing difference not remarkable with Liuwei Anxiao.The results are shown in Table 4.
The impact that table 4 is secreted CSG gastric mucosa epithelial cell mucin
Compare with Normal group,
#p<0.05,
##p<0.01; * P<0.05 is compared, * * P<0.01 with model control group; Compare with Liuwei Anxiao group of faling apart
Δp<0.05,
Δ Δp<0.01.
4.6 impacts on CSG rat stomach secretory function
Experimental result shows, compares with model group, and novel composing prescription 1,2 groups of rat gastric secretions have certain minimizing but there was no significant difference; The pH value of gastric juice has rising trend but there was no significant difference, points out the effect trend that novel composing prescription 1 and 2 tool has a certain upgrade gastric acidity, suppression CSG rat gastric juice excessive secretion; Determination of peptic activity result shows; compare with model control group and Liuwei Anxiao group of faling apart; novel composing prescription 1,2 groups significantly can reduce pepsic abnormal activity (p < 0.05), points out it to have and significantly alleviates the erosive damage of pepsin to gastric mucosa.Liuwei Anxiao is loose also has certain effect to These parameters but effect is not remarkable.The results are shown in Table 5
Table 5 is on the impact of CSG rat stomach secretory function
Compare with Normal group,
#p<0.05,
##p<0.01; * P<0.05 is compared, * * P<0.01 with model control group; Compare with Liuwei Anxiao group of faling apart
Δp<0.05,
Δ Δp<0.01.
4.7 impacts on CSG rat stomach microcirculatory blood flow
Compare with Normal group, model control group rat stomach body, pyloric part stomach microcirculatory blood flow significantly reduce; Administration is after 30 days, compare with model control group, novel composing prescription 1,2 groups of microcirculatory blood flows all significantly increase (p < 0.05), and wherein novel composing prescription 1 group and Liuwei Anxiao group of faling apart compares and has remarkable increase (p < 0.05).Novel composing prescription 1 group and Liuwei Anxiao be loose, and to organize comparing difference not remarkable.The results are shown in Table 6.
Table 6 is on the impact of CSG rat stomach blood flow
Compare with Normal group,
#p<0.05,
##p<0.01; * P<0.05 is compared, * * P<0.01 with model control group; Compare with Liuwei Anxiao group of faling apart
Δp<0.05,
Δ Δp<0.01.
4.8 impacts on CSG rat stomach secretin (GAS), motilin (MTL) level
Experimental result shows, administration is after 30 days, and compare with model control group and Liuwei Anxiao group of faling apart, the content of novel composing prescription 1,2 groups of motilin in plasma is significantly increased, and has significant difference (p < 0.05); And for serum GAS content, novel composing prescription 1,2 groups is similar with vitacoenzyme tablet group, all there is reduction trend but there was no significant difference, thus reduce gastric acid secretion, protection mucosal lesion position.The results are shown in Table 7.
Table 7 is on the impact of CSG rat stomach secretin (GAS), motilin (MTL) level
Compare with Normal group,
#p<0.05,
##p<0.01; * P<0.05 is compared, * * P<0.01 with model control group; Compare with Liuwei Anxiao group of faling apart
Δp<0.05,
Δ Δp<0.01
In sum; novel composing prescription medicine all has therapeutical effect significantly to chronic superficial gastritis; this effect is mainly manifested in and suppresses gastric mucosa inflammation and reduce gastric mucosa pathologic damage; promote stomach blood flow; reduce the content of serum GAS, suppress G cell activation, thus reduce gastric acid secretion; protection mucosal lesion position, action effect and vitacoenzyme tablet similar.
Claims (5)
1. be used for the treatment of a Tibetan medicinal composition for chronic superficial gastritis, it is characterized in that, the active component be made up of the crude drug of following weight portion forms: Radix Inulae 50 parts, Radix Et Rhizoma Rhei 200 parts, Rhizoma Kaempferiae 100 parts, forge calcite 250 parts, Fructus Chebulae 150 parts.
2. the Tibetan medicinal composition being used for the treatment of chronic superficial gastritis according to claim 1, is characterized in that, described active component is that the fine powder after being pulverized by described crude drug is made.
3. the Tibetan medicinal composition being used for the treatment of chronic superficial gastritis according to claim 1, it is characterized in that, described active component is after the Radix Inulae in described crude drug, Radix Et Rhizoma Rhei, Rhizoma Kaempferiae, Fructus Chebulae are adopted conventional method extraction, drying, add and forge calcite, be jointly ground into fine powder and obtain.
4. the application of the Tibetan medicinal composition described in any one of claim 1-3 in preparation treatment chronic superficial gastritis medicine.
5. the application of Tibetan medicinal composition according to claim 4 in preparation treatment chronic superficial gastritis medicine, it is characterized in that, in described Tibetan medicinal composition active component, add the various customary adjuvant that pharmaceutics allows, be prepared into acceptable powder, pill, capsule, granule or tablet on pharmaceutics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510447729.8A CN104940770B (en) | 2015-07-27 | 2015-07-27 | A kind of Tibetan medicinal composition and its application for being used to treat superficial gastritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510447729.8A CN104940770B (en) | 2015-07-27 | 2015-07-27 | A kind of Tibetan medicinal composition and its application for being used to treat superficial gastritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104940770A true CN104940770A (en) | 2015-09-30 |
| CN104940770B CN104940770B (en) | 2018-02-23 |
Family
ID=54156193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510447729.8A Active CN104940770B (en) | 2015-07-27 | 2015-07-27 | A kind of Tibetan medicinal composition and its application for being used to treat superficial gastritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104940770B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109331054A (en) * | 2018-11-23 | 2019-02-15 | 内蒙古民族大学附属医院 | A kind of anaesthetic that treating stomach trouble and its preparation process |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546133A (en) * | 2003-12-04 | 2004-11-17 | 玲 张 | Prescription and preparing process and formulation of Liuwei Nengxiao capsule |
| CN102526574A (en) * | 2011-12-28 | 2012-07-04 | 江西青春康源制药有限公司 | Traditional Chinese medicine preparation-Liuwei Anxiao Pills and preparing method thereof |
-
2015
- 2015-07-27 CN CN201510447729.8A patent/CN104940770B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546133A (en) * | 2003-12-04 | 2004-11-17 | 玲 张 | Prescription and preparing process and formulation of Liuwei Nengxiao capsule |
| CN102526574A (en) * | 2011-12-28 | 2012-07-04 | 江西青春康源制药有限公司 | Traditional Chinese medicine preparation-Liuwei Anxiao Pills and preparing method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 方英杰: "六味安消胶囊治疗功能性消化不良临床观察", 《中国中西医结合学会第十三次全国消化系统疾病学术研讨会论文汇编》 * |
| 马学清: "六味安消胶囊组方原理探讨", 《中国中西医结合学会第十三次全国消化系统疾病学术研讨会论文汇编》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109331054A (en) * | 2018-11-23 | 2019-02-15 | 内蒙古民族大学附属医院 | A kind of anaesthetic that treating stomach trouble and its preparation process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104940770B (en) | 2018-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2486914C2 (en) | Combined therapy for patients with neurological disorders and cerebral infarction | |
| WO2009062338A1 (en) | A lactogenic chinese medicine for treatment and prevention of gynecopathy, methods of preparation and uses thereof | |
| CN102365091A (en) | Compositions for preventing or improving gastrointestinal diseases | |
| CN103520293B (en) | Improve and treat the Chinese medicine for oral administration of constipation | |
| CN101002929A (en) | Medicine for treating functional hypopepsia or complicating Helicobacter pylori infection, and its preparing method | |
| CN105641433A (en) | Health food composition and preparation method thereof | |
| CN105287812A (en) | Medicine composition for treating irritable bowel syndromes and application of medicine composition | |
| CN105250821A (en) | Traditional Chinese medicine compound preparation for treating ulcerative colitis and preparation method thereof | |
| CN104940770A (en) | Tibetan medicine composition for treating superficial gastritis and application thereof | |
| CN105456550B (en) | Gastric mucosa damage prophylactic treatment compound and the preparation method and application thereof | |
| CN105079227A (en) | Application of traditional Chinese medicine composition in preparing medicine for treating radiation-induced pulmonary injury | |
| CN101693090B (en) | Technology for preparing compound kidney inflammation tablets | |
| CN102106993B (en) | Chinese medicinal composition for treating fatty liver and preparation method thereof | |
| CN109224038A (en) | A kind of Chinese medicine composition of the evodia rutaecarpa containing guiding drug and its preparation method and application for treating obstruction of collaterals by blood stasis type liver fibrosis | |
| CN104784670A (en) | Pharmaceutical composition for treating myocarditis and preparation method of pharmaceutical composition | |
| CN102641342B (en) | A kind of Chinese medicine extract and preparation method for the treatment of nephropathy | |
| CN104800565B (en) | A kind of Chinese medicine and preparation method for the treatment of esophageal carcinoma | |
| CN104587316B (en) | Anti-gout composition and its preparation method and application | |
| TWI844079B (en) | Chinese medicine composition and its preparation method and application | |
| CN104224929B (en) | A kind of Chinese medicine composition and its preparation method and application being used for the treatment of flu and upper respiratory tract infection | |
| CN114617896B (en) | Application of forsythoside A in preparation of medicine for preventing or treating severe acute pancreatitis complicated with brain injury | |
| CN115715782B (en) | Traditional Chinese medicine composition for preventing and treating ulcerative colitis and application thereof | |
| CN102824593A (en) | Chinese patent medicine for treating chronic renal failure | |
| CN108653607B (en) | Traditional Chinese medicine composition for treating ulcerative colitis and preparation method thereof | |
| CN102727672B (en) | A kind of Chinese medicine composition for the treatment of hypertensive nephropathy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 250101 Shandong Province Jinan Hi-tech Zone Comprehensive Bonded Zone No. 1 North Section of Gangxing No. 3 Road Jinan Yaogu R&D Platform Area No. 3 Floor 8001 Patentee after: Jinhe Tibetan Medicine (Shandong) Health Industry Co.,Ltd. Address before: 250101 room 501-506, Shun Feng Road, Ji'nan hi tech Zone, Shandong, 501-506 Patentee before: SHANDONG JINHE DRUG RESEARCH DEVELOPMENT Co.,Ltd. |